Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Driver-directed therapeutics have revolutionized cancer treatment, presenting similar or better efficacy compared to traditional chemotherapy and substantially improving quality of life. Despite significant advances, targeted therapy is greatly limited by resistance acquisition, which emerges in nearly all patients receiving treatment. As a result, identifying the molecular modulators of resistance is of great interest. Recent work has implicated protein kinase C (PKC) isozymes as mediators of drug resistance in non-small cell lung cancer (NSCLC). Importantly, previous findings on PKC have implicated this family of enzymes in both tumor-promotive and tumor-suppressive biology in various tissues. Here, we review the biological role of PKC isozymes in NSCLC through extensive analysis of cell-line-based studies to better understand the rationale for PKC inhibition. PKC isoforms α, ε, η, ι, ζ upregulation has been reported in lung cancer, and overexpression correlates with worse prognosis in NSCLC patients. Most importantly, PKC isozymes have been established as mediators of resistance to tyrosine kinase inhibitors in NSCLC. Unfortunately, however, PKC-directed therapeutics have yielded unsatisfactory results, likely due to a lack of specific evaluation for PKC. To achieve satisfactory results in clinical trials, predictive biomarkers of PKC activity must be established and screened for prior to patient enrollment. Furthermore, tandem inhibition of PKC and molecular drivers may be a potential therapeutic strategy to prevent the emergence of resistance in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of PKC can upregulate several molecular pathways, including Akt, signal transducer and activator of transcription 3 (STAT3), nuclear factor‐κB (NF‐κB) and apoptotic pathways, to regulate tumorigenesis and metastasis [112].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [112]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The binding of ligands to their receptors can activate phospholipase C, leading to the upregulation of cytosolic concentrations of the activators of PKC signaling, diacylglycerol (DAG) and Ca++ [112, 113].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Lung cancer is the most prevalent cancer and the leading cause of cancer-related mortality worldwide, with an estimated 2,093,900 new cases and 1,761,000 deaths annually [1,2].”
BackgroundSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725 · cited 2×
“The discovery of PKC activation by tumor-promoting agent phorbol 12-myristate 13-acetate (PMA) in 1982 [28] drew attention to this family of kinases based on the plethora of cell biologic responses to PMA and other phorbol esters, warranting extensive research that implicated PKC isozymes in various pathologies, inclu…”
BackgroundZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908 · cited 1×
“The current clinical outcomes for lung cancer patients are far from satisfactory, and novel treatments must be developed that improve overall survival (OS) [3].”
BackgroundLung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484 · cited 1×
“NSCLC accounts for the largest subset of lung cancer cases, roughly 85%, and is further categorized into adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma [4,5].”
BackgroundCoussens, L., Parker, P. J., Rhee, L., Yang-Feng, T. L., Chen, E., Waterfield, M. D., Francke, U., & Ullrich, A. (1986) · Science · doi:10.1126/science.3755548 · Cited by 1,042
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Geraldes, P., & King, G. L. (2010) · Circulation Research · doi:10.1161/circresaha.110.217117 · Cited by 985
Structural Basis of Protein Kinase C Isoform Function
Steinberg, S. F. (2008) · Physiological Reviews · doi:10.1152/physrev.00034.2007 · Cited by 872 · cited 1×
“Biochemical analysis of PKCs revealed a highly conserved C-terminal catalytic domain, with a variable N-terminal regulatory domain (Figure 2) [26].”
BackgroundInoue, M., Kishimoto, A., Takai, Y., & Nishizuka, Y. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41010-6 · Cited by 862 · cited 1×
“Briefly, PKCs were initially discovered in 1977 by the group of Yasutomi Nishizuka [18].”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“The activation of PKC can upregulate several molecular pathways, including Akt, signal transducer and activator of transcription 3 (STAT3), nuclear factor-κB (NF-κB) and apoptotic pathways, to regulate tumorigenesis andmetastasis [112].”
BackgroundOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“Interestingly, different PKC isoforms play varying roles in tumorigenesis and metastasis (94).”
BackgroundZamanian, M. Y., Alsaab, H. O., Golmohammadi, M., Yumashev, A., Jabba, A. M., Abid, M. K., Joshi, A., Alawadi, A. H., Jafer, N. S., Kianifar, F., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4030 · Cited by 105
“82”
Silnitsky, S., Rubin, S. J. S., Zerihun, M., & Qvit, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417600 · Cited by 48
“PKC signaling pathways contribute to the key cellular responses central to asthma [283–285], chronic obstructive pulmonary disease (COPD) [286], idiopathic pulmonary fibrosis (IPF) [287], acute respiratory distress syndrome (ARDS) [288,289], and lung cancer [167,290], to mention a few.”
BackgroundHe, Q., Qu, M., Bao, H., Xu, Y., Shen, T., Tan, D., Barkat, M. Q., Xu, C., Zeng, L., & Wu, X. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.003 · Cited by 43
Metadata
- Authors
- Sadeghi, M. M., Salama, M. F., & Hannun, Y. A.
- Affiliations
- Department of Biochemistry, Molecular and Cellular Biology, Stony Brook University, Stony Brook, NY 11794, USA
- Mansoura University (EG)
- Stony Brook University Hospital (US)
- Corresponding author
- Hannun, Yusuf A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-24
- Volume
- 22
- Issue
- 11
- Pages
- 5527
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8197251
- OpenAlex
- W3164693058
- Cited by
- 31
- References
- 119
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 4 · 2021: 1
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Veterans Affairs (I01 BX004621)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- protein kinase C, non-small cell lung cancer, drug resistance, tyrosine kinase inhibitors, PKC isoforms, predictive biomarkers, combination therapy, targeted therapy
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Lung Neoplasms, Prognosis, Protein Kinase C, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Protein Isoforms, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.3390/ijms22115527
- The paper
- Sadeghi, M. M., Salama, M. F., & Hannun, Y. A. (2021). Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22115527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.